Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100

Journal of Acquired Immune Deficiency Syndromes

Volumn 25, Issue 2, 2000, Pages 99-102

  Tremblay, Cécile L ^a   Kollmann, Christopher ^a   Giguel, Françoise ^a   Chou, Ting Chao ^b   Hirsch, Martin S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CXCR4; Drug interactions; Fusion; HIV 1 coreceptor inhibitors; Viral entry

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS ADSORPTION; VIRUS CELL INTERACTION;

EID: 0034298213     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200010010-00001     Document Type: Article

References (15)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Latent infection of CD4 T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
3. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
4. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy
5. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
6. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
7. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor
8. Inhibition of T-tropic strains by selective antagonization of the chemokine receptor CXCR4
9. Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual
10. HIV-1 selection in response to inhibition of virus fusion and entry
11. Determinants of human immunodeficiency virus type 1 resistance to gp-41-derived inhibitory peptides
12. Bicyclams as CXCR4 antagonists
13. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers
14. The median-effect principle and the combination index for quantitation of synergism and antagonism
15. Combination antiretroviral therapy